Drug Trial Radar · NCT07513181
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Dec 14, 2028
Study completion Dec 14, 2028
Sponsor
- Lead sponsor
- Athos Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
Conditions
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Autoimmune Diseases
Interventions
ATH-063Drug
Three 50 mg capsules, total dose 150 mg.
PlaceboOther
Identical capsule to the drug without the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Remission at Week 12Time frame: At Week 12
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Miami Clinical Research
Miami, Florida · Recruiting
GCP Clinical Research
Tampa, Florida · Recruiting
Gastroenterology Consultants, P.C.
Roswell, Georgia · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.